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hiopurines are key immuno-Tsuppressants for the treatment
of inflammatory bowel disease. Thio-
purine use during pregnancy has not
been prohibited, but its safety is still
debated.1,2 Additionally, it has been
revealed that several genetic poly-
morphisms are associated with thio-
purine toxicities3; however, the effects
of parental or offspring genotype on
the safety of thiopurine use during
pregnancy have not been investigated.
NUDT15 (nucleoside diphosphate-
linked moiety X-type motif 15) is
responsible for the inactivation of




NUDT15 are strongly associated with
cytopenia during thiopurine use.4,5 In
particular, the c.415C>T single-
nucleotide polymorphism, which in-
duces p.Arg139Cys (R139C) and the
loss of normal enzymatic activity, is
clinically important in East Asians
because it penetrates more than 10%
of them and frequently causes severeFigure 1. Thiopurine use during pregna
duces harmful effects on offspring. T
quency of Nudt15 genotype in neonata
generated by Nudt15þ/R138C female mice
Nudt15þ/þ female mice (B) that were mat
Nudt15þ/R138C male mice and treated w
indicated MP dose during pregnancy. D
sulfoxide was administered instead of M
control. The numbers of analyzed neonat
and parental mice are presented for ea
dose. DMSO, dimethyl sulfoxide.cytopenia.4 We recently established
knock-in mice harboring a p.Arg138Cys
mutation (Nudt15R138C), which corre-
sponds to human NUDT15 R139C,
and demonstrated that thiopurine
administration causes hematopoietic
stem cell (HSC) toxicity in Nudt15þ/
R138C or Nudt15R138C/R138C mice (see
SupplementaryMethods).6 In this study
using ourmousemodel, we investigated
whether thiopurine use during preg-
nancy differentially affects offspring,
based on their NUDT15 genotype.
Our previous report demonstrated
that the long-term (>2 months) sur-
vivable dose of mercaptopurine (MP)
is 1.0 mg/kg for Nudt15þ/þ, 0.5 mg/kg
for Nudt15þ/R138C, and 0.2 mg/kg for
Nudt15R138C/R138C adult mice.6 Thus,
we administered the same doses of MP
to Nudt15þ/R138C or Nudt15þ/þ preg-
nant mice, respectively, and then
characterized the Nudt15 genotypes of
the neonatal mice. Nudt15þ/R138C fe-
male mice that were mated with
Nudt15þ/R138C male mice generated
neonatal mice in a Mendelian fashion
under 0 mg/kg and 0.1 mg/kg MP
treatment (see Supplementary
Methods). However, few to zero
Nudt15R138C/R138C neonatal mice were
generated under 0.2 mg/kg or 0.5 mg/
kg MP treatment, respectively
(Figure 1A). Similarly, Nudt15þ/þ fe-
male mice that were mated with









ch MPgenerate Nudt15þ/R138C neonatal mice
under 1.0 mg/kg MP treatment
(Figure 1B). These data indicate that
the therapeutic MP dose for pregnant
mice could be deleterious to offspring
harboring more Nudt15R138C allele than
the female parent.
Next, to investigate fetal abnormal-
ities caused by MP treatment during
pregnancy, we analyzed the Nudt15 ge-
notypesof fetalmice fromNudt15þ/R138C
pregnant mice that were administered
0.2mg/kg or 0.5 mg/kgMP after mating
with Nudt15þ/R138C male mice. On em-
bryonic day 14.5, the number of
Nudt15R138C/R138C fetal mice was
reduced under 0.2 mg/kg MP treatment
and eliminated under 0.5 mg/kg MP
treatment, indicating that thiopurine use
during pregnancy can lead to embryonic
lethality in Nudt15R138C/R138C
offspring (Supplementary Figure 1).
Nudt15R138C/R138C fetal mice that sur-
vived 0.2 mg/kg MP treatment during
pregnancy tended to be paler
(Figure 2A) and were significantly
smaller in size thanNudt15þ/þ fetalmice
(Figure2B).Wepreviously reported that
hematopoietic tissue is promptly injured
by MP treatment in Nudt15R138C/R138C
adultmice, andHSCsare damagedbyMP
in a Nudt15R138C allele number-
dependent manner.6 Therefore, we
determined the number of HSCs in each
fetal liver, the center of hematopoiesis in
fetal mice. To do this, fetal HSCs that are
Figure 2. Thiopurine induces hemato-
poietic toxicity in fetal mice. Represen-
tative appearance (A) and the
crown-rump length (B) of Nudt15þ/þ,
Nudt15þ/R138C, or Nudt15R138C/R138C fetal
mice on embryonic day 14.5 generated by
Nudt15þ/R138C female mice that were
mated with Nudt15þ/R138C male mice and
treated with 0.2 mg/kg MP during preg-
nancy. Scale bars indicate 5 mm. The
numbers of parental male and female mice
are 14, and 15, respectively. (C) The ab-
solute number of HSCs in Nudt15þ/þ,
Nudt15þ/R138C, or Nudt15R138C/R138C fetal
liver on embryonic day 14.5 is plotted. The
means and standard deviations are indi-
cated by horizontal bars and vertical bars,
respectively. Significant P values with
analysis of variance followed by Tukey
test are described. DMSO, dimethyl
sulfoxide.
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CD48–CD150highLineage–c-KitþSca-1þ
population using multicolor staining7
were counted on embryonic day 14.5
(see Supplementary Methods and
Supplementary Figure 2). The number
of fetal HSCs was not altered in any of
the Nudt15 genotypes without MP
treatment (Figure 2C). However, it was
significantly reduced byMP treatment in
Nudt15þ/R138C fetal mice (P< .01; mean
number 1104 in dimethyl sulfoxide and
577 in MP) and in Nudt15R138C/R138C
fetal mice (P< .01; mean number 927 in
dimethyl sulfoxide and 402 in MP), but
not in Nudt15þ/þ fetal mice (P ¼ .39;
mean number 1004 in dimethyl sulf-
oxide and 820 in MP). Finally, the num-
ber of HSCs in Nudt15R138C/R138C fetal
livers was significantly reduced to less
than 50% of that in Nudt15þ/þ fetal
livers by MP treatment during gestation
(P ¼ .0089).
The current study clearly demon-
strates that thiopurine use during
pregnancy can cause serious damage tofetal mice, depending on the Nudt15
genotype of the offspring. In particular,
Nudt15þ/R138C offspring in Nudt15þ/þ
pregnant mice and Nudt15R138C/R138C
offspring in Nudt15þ/R138C pregnant
mice are not safe when the pregnant
mice are exposed to therapeutic MP
dose. Because the placental perme-
ability of thiopurines andmetabolites is
unknown inmice, our datamaypossibly
overestimate thiopurine fetal toxicity in
humans. However, it has been reported
that thioguanines including thio-gua-
nosine-5’-triphosphate, which is the
active thiopurine metabolite for cyto-
toxicity and is directly metabolized by
NUDT15, can cross human placenta.8 In
addition, cases of anemia in thiopurine-
exposed infants have been reported,
although there is no description of
NUDT15.9 Our data also show that fetal
HSCs can be damaged by thiopurine use
during pregnancy in a Nudt15 allele
number-dependent manner.
In summary, given the ethical diffi-
culty of conducting further prospectiveclinical studies, thiopurine use during
pregnancy should be considered with
caution based on the NUDT15 genotype.
Particularly, the paternalNUDT15R139C
alle is recommended to be examined in
the decision to use thiopurine during
pregnancy because it is critical to deter-
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